Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 8/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.39 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272301 | 0.86 | TRPA1 (0.57) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL31255993 | 0.80 | TRPA1 (0.44) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6382617 | 0.80 | TRPA1 (0.44) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2240307 | 0.80 | TRPA1 (0.54) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6389633 | 0.80 | TRPA1 (0.62) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29241240 | 0.79 | TRPA1 (0.48) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL113390 | 0.79 | TRPA1 (0.43) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18318359 | 0.79 | PLAU (0.47) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15195532 | 0.79 | TNF (0.46) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6380931 | 0.77 | TRPA1 (0.43) | TRPA1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796458-B2 | Cyclohexylamine isoquinolone derivatives | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-8742116-B2 | Cycloalkylamine substituted isoquinolone derivatives | SANOFI (FR) | 2014-06-03 | — | — | US | disclosed |
| US-8461144-B2 | Substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120316152-A1 | SUBSTITUTED ISOQUINOLINEAND ISOQUINOLINONE DERIVATIVES | SANOFI (FR) | 2012-12-13 | — | — | US | disclosed |
| US-8278294-B2 | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of Rho-kinase | SANOFI (FR) | 2012-10-02 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316152-A1 | SUBSTITUTED ISOQUINOLINEAND ISOQUINOLINONE DERIVATIVES | MYLK2, RHOT2, MYLK | TRPA1 4877/4885CYP1A2 3631/4885CYP3A4 4639/4885 |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | MYLK2, MYLK, MYLK3 | TRPA1 4838/4885CYP1A2 1903/4885CYP3A4 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.